PINL
Pinealon
A synthetic tripeptide, Glu-Asp-Arg. As with the other short synthetic peptides in this group, no receptor target has been established in the published literature and none is stated here.
No registered human study names Pinealon as an intervention. ClinicalTrials.gov holds no trial of it, so there is no trial evidence to read — a fact about the public record rather than proof the compound does nothing. No FDA-approved product contains Pinealon. 1 paper naming it was published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Pinealon; the registry search is fuzzy, so every match is re-checked. None of this says whether Pinealon works or is safe.
FDA status
Research only
Human studies
0
Furthest phase
—
Papers, 10 yr
1
Readership
2,562
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
No registered human study
0
Registered human studies
None
No FDA-approved product contains it
No study of Pinealon in humans is registered on ClinicalTrials.gov. That is a fact about the public record, not a statement that the compound does nothing — but it does mean there is no trial evidence to read, and anyone telling you otherwise should be asked for the registration number. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Pinealon is, and what it has been studied for
Pinealon is tracked here.
No registered trial names Pinealon as an intervention, so there is no condition it has been formally studied in. It does have a literature: 1 indexed paper name it in the last ten years. That work is laboratory and animal research, and a paper is not a trial.
Is anyone studying Pinealon?
Papers published each year that name Pinealon in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 0 | 0 | Yes |
| 2018 | 0 | 0 | Yes |
| 2019 | 0 | 0 | Yes |
| 2020 | 0 | 0 | Yes |
| 2021 | 0 | 0 | Yes |
| 2022 | 0 | 0 | Yes |
| 2023 | 0 | 0 | Yes |
| 2024 | 0 | 0 | Yes |
| 2025 | 0 | 0 | Yes |
| 2026 | 1 | 0 | No |
1 papers between 2017 and 2026. A paper counts when “Pinealon” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Pinealon
1 indexed papers name Pinealon in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
- Pinealon protects the rat offspring from prenatal hyperhomocysteinemia
- Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes
- EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION
- Regulation of content of cytokines in blood serum and of caspase-3 activity in brains of old rats in model of sharp hypoxic hypoxia with Cortexin and Pinealon
- Pinealon and Cortexin influence on behavior and neurochemical processes in 18-month aged rats within hypoxia and hypothermia
- Comparative analysis of different methods of geroprotective
- Investigation of antihypoxic properties of short peptides
Collected 2026-08-02from PubMed, phrase-matched on “Pinealon” in title and abstract. Run the same search.
About Pinealon
A synthetic tripeptide, Glu-Asp-Arg. As with the other short synthetic peptides in this group, no receptor target has been established in the published literature and none is stated here.
- Also known as
- EDR peptide
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.